Search hospitals > Florida > Fort Lauderdale
Holy Cross Hospital
Claim this profileFort Lauderdale, Florida 33308
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
261 reported clinical trials
17 medical researchers
Summary
Holy Cross Hospital is a medical facility located in Fort Lauderdale, Florida. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Holy Cross Hospital is involved with conducting 261 clinical trials across 408 conditions. There are 17 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
ER positive
HER2 negative
Top PIs
Tareq Al BaghdadiSaint Joseph Mercy Hospital7 years of reported clinical research
Expert in Cancer
Expert in Tumors
69 reported clinical trials
127 drugs studied
Christopher M. Reynolds, MDSaint Joseph Mercy Hospital4 years of reported clinical research
Expert in Cancer
Studies Lung Cancer
45 reported clinical trials
99 drugs studied
Philip J. StellaSaint Joseph Mercy Hospital4 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
38 reported clinical trials
89 drugs studied
Elie G. DibSaint Joseph Mercy Hospital4 years of reported clinical research
Expert in Cancer
Studies Multiple Myeloma
34 reported clinical trials
94 drugs studied
Clinical Trials running at Holy Cross Hospital
Breast Cancer
Bladder Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Bladder Carcinoma
Multiple Myeloma
Oropharyngeal Carcinoma
Heart Failure
Squamous Cell Carcinoma
Sacituzumab Govitecan
for Triple-Negative Breast Cancer
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumors do express PD-L1.
Recruiting4 awards Phase 3
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Imlunestrant
for Early Breast Cancer
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
Recruiting2 awards Phase 36 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Holy Cross Hospital?
Holy Cross Hospital is a medical facility located in Fort Lauderdale, Florida. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Holy Cross Hospital is involved with conducting 261 clinical trials across 408 conditions. There are 17 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.